Scinai Immunotherapeutics Ltd.

NasdaqCM SCNI

Scinai Immunotherapeutics Ltd. Debt to Equity Ratio for the year ending December 31, 2023

Scinai Immunotherapeutics Ltd. Debt to Equity Ratio is NA for the year ending December 31, 2023. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
SV Wall Street
NasdaqCM: SCNI

Scinai Immunotherapeutics Ltd.

CEO Mr. Amir Reichman M.B.A., M.Sc.
IPO Date May 11, 2015
Location Israel
Headquarters Jerusalem BioPark Building
Employees 31
Sector Healthcare
Industries
Biotechnology Pharmaceuticals Vaccines
Description

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

StockViz Staff

February 7, 2025

Any question? Send us an email